GSK, Sanofi start trials of Covid-19 vaccine

Sanofi and GSK said they had started a Phase 1/2 clinical trial for Covid-19 vaccine involving 440 people in the US.

The companies on Thursday said they anticipated first results in early December to support the initiation of a Phase 3 trial in the same month. If data are sufficient for a license application, the duo said they planned to request regulatory approval in the first half of 2021.

The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.

There are currently more than 160 vaccines in development globally, including trials being conducted by Moderna, AstraZeneca, and a collaboration between Pfizer and BioNTech.